XERS ▼ -0.6% - Xeris Biopharma Holdings, Inc. $XERS Xeris Hosts Webinar Detailing Its Comprehensive Development Program for XP-8121, an Investigational, Once-Weekly Subcutaneous Levothyroxine for Hypothyroidism Xeris Biopharma (XERS) fell 0.6% today following the company's webinar on its development program for XP-8121, an investigational once-weekly subcutaneous levothyroxine treatment for hypothyroidism. The modest decline suggests investors may have had limited reaction to the clinical update, or that the market was awaiting more concrete efficacy or timeline data beyond the program overview. 09-SEP-2026 08:30 AM ET